Re: Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
Chamberlain
Marc C
MC
Glantz
Michael J
MJ
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004660:Encephalitis / Q000139:chemically induced; D005260:Female; D006801:Humans; D007278:Injections, Spinal; D017254:Leukemic Infiltration / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D008081:Liposomes; D008297:Male; D008578:Meninges / Q000473:pathology; D008581:Meningitis / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D010211:Papilledema / Q000139:chemically induced; D011128:Polyradiculopathy / Q000139:chemically induced; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012640:Seizures / Q000139:chemically induced
D008081:Liposomes; D003561:Cytarabine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate